What does CUSIP 221015100 represent in this 13F holders report?

CUSIP 221015100 is the security identifier for CRVS - Corvus Pharmaceuticals, Inc. - COMMON STOCK used to aggregate holder disclosures.

How many institutions held CRVS - Corvus Pharmaceuticals, Inc. - COMMON STOCK in Q3 2021?

55 institutional investors reported CRVS - Corvus Pharmaceuticals, Inc. - COMMON STOCK for Q3 2021. Use the holders table for investor-level position and value details.

Corvus Pharmaceuticals, Inc. - COMMON STOCK (CRVS)

CUSIP: 221015100

Q3 2021 13F Holders as of 30 Sep 2021

Security type / class: Equity / COMMON STOCK
Total 13F shares: 28,180,241
Total 13F value: $136,388,000
Share change: +4,492,111
Put/Call ratio: 41%
SEC-reported price per share: $4.84
Number of holders: 55
Value change: +$22,907,893
Number of buys: 30
Number of sells: 26
Shares outstanding: 84,416,811

Security key

221015100

Report period

Q3 2021

Institutions

Top holders

CRVS full security history Ownership snapshot Full 13F holder table Corvus Pharmaceuticals, Inc. SEC filings Corvus Pharmaceuticals, Inc. company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of CRVS - Corvus Pharmaceuticals, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

ORBIMED ADVISORS LLC

Disclosed value leader

ORBIMED ADVISORS LLC

Comparable rows

15/15

Latest evidence

30 Jun 2021

13F 3/4/5 Lead comparable stake: 9.5% Showing 1-6 of 15 holder rows.

Quick read

ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 9.5%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ORBIMED ADVISORS LLC's linked filing trail.

Comparable ownership Top 5

ORBIMED ADVISORS LLC 9.5%

BVF INC/IL 4.4%

EcoR1 Capital, LLC 4.2%

ADAMS STREET PARTNERS LLC 3.9%

VANGUARD GROUP INC 1.3%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
ORBIMED ADVISORS LLC	13F Company 13F	9.5%	$21,502,000 8,053,298 shares	—	30 Jun 2021
BVF INC/IL	13F Company 13F	4.4%	$9,822,000 3,678,626 shares	—	30 Jun 2021
EcoR1 Capital, LLC	13F 3/4/5 Company · 10%+ Owner 13F 3/4/5	4.2%	$9,557,000 3,579,377 shares	—	30 Jun 2021
ADAMS STREET PARTNERS LLC	13F Company 13F	3.9%	$8,746,000 3,275,616 shares	—	30 Jun 2021
VANGUARD GROUP INC	13F Company 13F	1.3%	$2,962,000 1,109,218 shares	—	30 Jun 2021
CHI Advisors LLC	13F Company 13F	0.85%	$1,920,000 719,132 shares	—	30 Jun 2021

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2021

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

28,180,241

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2021 vs Q2 2021 Across Filers

Q2 2021 holders

Q3 2021 holders

Holder diff

Investor	Q2 2021 Shares	Q3 2021 Shares	Share Diff	Share Chg %	Q2 2021 value	Q3 2021 value	Value change	Value Chg %